Tedros Adhanom Ghebreyesus & Mapp Biopharmaceutical

Tedros Adhanom Ghebreyesus: WHO Director-General; announced clinical trial start and warned of pandemic threat.

Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus>>>, the Director-General of the World Health Organization>>>, has declared the Ebola outbreak a public health emergency of international concern and is actively involved in coordinating the response, visiting affected areas and urging international action.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.